Violante OR, Porres AM

Language: Spanish
References: 66
Page: 386-392
PDF size: 67.71 Kb.

ABSTRACT

Obesity and diabetes have converted in two of the most important world-wide epidemic diseases, constituting one of the principal causes of morbid-mortality around the world. In terms of epidemiology it is prognosticated that diabetes will increase 35% in its prevalence world-wide, being more critical in underdeveloped countries. In Mexico we have witnessed a dramatic increase in our prevalences of overweight and obesity, as well as for diabetes in the last two decades. We mentioned the significant etiologic factors implicated in the genesis of development of obesity and its related diseases. Nowadays is transcendental the impact of overweight and obesity in children and young adolescents in the development of early-onset of diabetes. Only 48.2% of all obese patients in the United States of America receive advice from general physicians to lose weight during their follow-up, this article emphasizes on the prevention of obesity.

REFERENCES

1. Harris MI. Prevalence of diabetes impaired fasting glucose and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1988;21:518-24.

2. Mokdad A. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195-200.

3. WHO. Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series, No. 894, WHO: Geneva, 2000.

4. King H. Global Burden of Diabetes, 1995-2025. Diabetes Care 1998;21:1414-31.

5. Mokdad A. Diabetes trends in the US: 1990-1998. Diabetes Care 2000;23:1278-83.

6. Yanovski S. Review article. Obesity. N Engl J Med 2002; 346:591-602.

7. Flegal MD. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998;22:39-47.

8. Editorial: Getting a handel on obesity. Lancet 2002;359:1955.

9. Must A. The Disease burden associated with overweight and obesity. JAMA 1999;282:1523-9.

10. Rivera JA. Epidemiological and nutritional transition in México: rapid increase of non-communicable chronic diseases and obesity. Public Health Nutrition 2002;5(1A):113-22.

11. Velázquez M. Prevalencia e interrelación de enfermedades crónicas no transmisibles y factores de riesgo cardiovascular en México. Arch Cardiol Mex 2003;73:62-77.

12. Lara A. Grupo ENSA 2000. Comunicación personal, datos por publicar.

13. Lyznicki J. Obesity: Assessment and management in primary care. Am Fam Physician 2001;63:2185-96.

14. Rossner S. Obesity: the entity of the XXI century. Int J Obesity 2002;26(Suppl 4):S2-S4.

15. Sokol R. The chronic disease of childhood obesity: The sleeping giant has awakened. J Pediatr 2000;136:711-13.

16. Maggio C. The prevention and treatment of obesity. Diabetes Care 1997;20:1744-66.

17. Resnick H. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Commun Health 2000;54:596-602.

18. Field A. Impact of overweight on the risk of developing common chronic diseases during a 10-yaer period. Arch Intern Med 2001;161:1581-86.

19. Hu FB. Diet, lifestyle and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790-7.

20. Ford ES. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997;146:214-22.

21. Colditz G. Weight as a risk factor for clinical diabetes in woman. Am J Epidemiol 1990;132:501-13.

22. Everhart JE. Duration of obesity increases incidence of NIDDM. Diabetes 1992;41:235-40.

23. Holbrook TL. The association of lifetime weight and weight control patterns with diabetes among men and women in an adult community. Int J Obesity 1989;13:723-9.

24. Hillier T. Characteristics of an adult population with newly diagnosed type 2 diabetes. Diabetes Care 2001;24:1522-27.

25. Mokdad A. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999;282:1519-22.

26. Aguilar C. Prevalence and characteristics of early-onset type 2 diabetes in Mexico. Am J Med 2002;113:569-74.

27. Lundgren H. Adiposity and adipose tissue distribution in relation to incidence of diabetes in women: Results from a prospective population study in Gothenburg, Sweden. Int J Obesity 1989;13:413-23.

28. Haffner S. Greater influence of central distribution of adipose tissue on incidence of non-insulin-dependent diabetes in women than in men. Am J Clin Nutr 1991;53:1312-7.

29. National Institutes of Health, National, Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998;6(Suppl 2):51S-209S.

30. Berber A. Anthropometric indexes in the prediction of type 2 diabetes mellitus, hypertension and dyslipidaemia in a Mexican population. Int J Obesity 2001;25:1-6.

31. Sánchez C, Lara A. Anthropometric cutoff for predicting chronic diseases in the Mexican National Health Survey 2000. Grupo ENSA 2000. Obes Res 2003;11:442-51.

32. Ludwing DS. Type 2 in children: primary care and public health considerations. JAMA 2001;286:1427-30.

33. Fagot-Campagna A. Type 2 diabetes among North American children and adolescents: An epidemic review and a public health perspective. J Pediatr 2000;136:664-72.

34. Rosenbloom AL. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999;22:3345-54.

35. Sinha R. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002;346:802-10.

36. Caprio S. Insulin resistance in childhood obesity. J Pediatr Endocrinol Metab 2002;15(suppl 1):487-92.

37. Martin BC. Role of glucose and insulin resistance in development of type 2 diabetes: results of a 25-year follow-up study. Lancet 1992;340:925-29.

38. Lillioja S. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 1993;329:1988-92.

39. Poitout V. Minireview: Secundary beta cell failure in type 2 diabetes: a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002;143:339-42.

40. Lewis GF. Disordered fat storage and mobilization in the patogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-29.

41. Paquot N. Hepatic insulin resistance in obese non-diabetic subject and type 2 diabetic subjects. Obes Res 2002;10:129-34.

42. Sinha R. Assessment of skeletal muscle triglyceride content by H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationship to insulin sensibility, total body fat and central adiposity. Diabetes 2002;51:1022-7.

43. Freemark M. Pharmacologic approaches to the Prevention of type 2 diabetes in high risk pediatric patients. J Clin Endocrinol Metab 2003;88:3-13.

44. Harris MI. Onset of the NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992;15:815-9.

45. James W. The metabolic challenge of obesity: the impact of weight management on improvement of metabolic risk factors. Int J Obes Relat Metab Disord 2002;26(Suppl 4):S1.

46. Fontanarosa P. Patients, physicians and weight control. JAMA 1999;282:1581-2.

47. Wee CC. Physician counseling about exercise. JAMA 1999;282:1583-8.

48. Galuska DA. Are health care professionals advising obese patients to lose weight ? JAMA 1999;282:1581-82.

49. Tuomilehto J. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;34:1343-50.

50. Eriksson K.F. Prevention of type 2 diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991;891-98.

51. Xiao-Ren P. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.

52. Knowler WC. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.

53. Nelson K. Diet and exercise among adults with type 2 diabetes. Diabetes Care 2002;25:1722-8.

54. National Institutes of Health, National, Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998;6 (suppl 2):51S-209S.

55. Atkinson R. Proposed standards for judging the success of the treatment of obesity. Ann Intern Med 1993; 119:677-80.

56. National Institutes of Health, National, Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998;6(Suppl 2):51S-209S.

57. UKPDS Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes. (UKPDS 33). Lancet 1998;352:854-65.

58. Nathan D. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342-9.

59. Grumbier B. Obesity and type 2 diabetes mellitus: A treatment challenge. Endocrinologist 2002;12:23-38.

60. Wing RR. Long term effects of modest weight loss in type 2 diabetic patients. Arch Intern Med 1987;147:1749-53.

61. Williamson D. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499-504.

62. Hollander P. Role of Orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998;21:1288-94.

63. McNulty S. A Randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with Metformin. Diabetes Care 2003;26:125-31.

64. Heymsfield S. Effects of weight loss with Orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-6.

65. Sjöstrom L. Xenical in the prevention of diabetes in obese subjects: A landmark study. Oral presentation. ICO 2002, Sao Paulo, Brazil.

66. Chiasson JL. Acarbose treatment and the risk of cardiovascular disease and hypertensionn in patients with impaired glucosa tolerance. The STOP-NIDDM Trial. JAMA 2003;290:486-94.